MEDI4736: Phase Ib/II started

Pharmacyclics Inc. (NASDAQ:PCYC, Sunnyvale, Calif.) began the open-label, U.S. Phase Ib/II PCYC-1135-CA trial to evaluate oral Imbruvica ibrutinib once daily in combination with AstraZeneca’s IV MEDI4736 in about 160 patients with non-small cell lung cancer (NSCLC), breast cancer and pancreatic cancer. Pharmacyclics’ Imbruvica is approved in the U.S. to treat Waldenstrom’s macroglobulinemia and chronic lymphocytic leukemia (CLL) in patients with a chromosome 17p deletion and patients who have received >1 prior therapy. The Bruton’s tyrosine kinase (Btk) inhibitor that covalently binds to cysteine residue 481 has accelerated approval to treat mantle cell lymphoma (MCL). ...